

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
February 12, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

February 12, 2010

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b):82-\_\_\_\_\_

NOVO NORDISK FILES ANNUAL REPORT WITH THE SEC

Novo Nordisk A/S has filed its Annual Report 2009 on Form 20-F for the financial  
year 2009 with the US Securities and Exchange Commission (SEC), incorporating by  
reference the Novo Nordisk A/S Annual Report 2009. The reports are available at  
the SEC's website, [www.sec.gov](http://www.sec.gov) as well as at [novonordisk.com](http://novonordisk.com) - Investors -  
Download centre (listed under 2009).

## Edgar Filing: NOVO NORDISK A S - Form 6-K

Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form at [novonordisk.com/investors/download-centre](http://novonordisk.com/investors/download-centre) or upon request to either tel no (+1) 609 919 7937 or by e-mail to [hmmm@novonordisk.com](mailto:hmmm@novonordisk.com). When e-mailing, please state the exact mailing address and the document(s) you wish to receive.

- o Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

Further information:

Media:

Elin K Hansen  
Tel: (+45) 4442 3450  
[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

Investors:

Klaus Bulow Davidsen  
Tel: (+45) 4442 3176  
[klda@novonordisk.com](mailto:klda@novonordisk.com)

Kasper Roseeuw Poulsen  
Tel: (+45) 4442 4471  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

In North America:

Sean Clements  
Tel: (+1) 609 514 8316  
[secl@novonordisk.com](mailto:secl@novonordisk.com)

In North America:

Hans Rommer  
Tel: (+1) 609 919 7937  
[hmmm@novonordisk.com](mailto:hmmm@novonordisk.com)

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 12, 2010

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer